Trial Profile
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Combination Treatment of Fimasartan/Atorvastatin in Patients With Essential Hypertension and Dyslipidemia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Atorvastatin/fimasartan (Primary) ; Atorvastatin; Fimasartan
- Indications Dyslipidaemias; Essential hypertension
- Focus Registrational; Therapeutic Use
- Acronyms FIESTA
- Sponsors Boryung Pharmaceutical
- 04 Nov 2019 Status changed from active, no longer recruiting to completed.
- 18 Mar 2019 Planned End Date changed from 28 Feb 2019 to 15 Apr 2019.
- 18 Mar 2019 Planned primary completion date changed from 30 Nov 2018 to 15 Apr 2019.